Beraprost modified release - Lung Biotechnology/Toray Industries
Alternative Names: Beraprost modified release lung rx; Beraprost MR - Lung Biotechnology/Toray Industries; Beraprost sodium modified release; Beraprost sodium MR; BPS-MRLatest Information Update: 30 Oct 2021
Price :
$50 *
At a glance
- Originator Toray
- Developer Lung Biotechnology
- Class 3-ring heterocyclic compounds; Alkynes; Antiplatelets; Benzofurans; Butyric acids; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pulmonary arterial hypertension
Most Recent Events
- 30 Nov 2013 Lung RX completes a phase II extension trial in Pulmonary Arterial Hypertension in USA, Belgium and Ireland (NCT00792571)
- 30 Dec 2011 Lung RX completes a phase II extension trial in Pulmonary Arterial Hypertension in USA, Belgium, Ireland, Czech Republic, Romania and Germany (PO) (NCT00990314)
- 30 Dec 2011 Lung RX completes a phase II trial in Pulmonary Arterial Hypertension in USA, Belgium, Ireland, Czech Republic, Romania and Germany (PO) (NCT00989963)